Page last updated: 2024-11-12

murabutide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

murabutide: adjuvant devoid of pyrogenicity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13996209
MeSH IDM0104104

Synonyms (5)

Synonym
murabutide
74817-61-1
DTXSID80868322
butyl 2-[2-(2-{[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}propanamido)propanamido]-5-amino-5-oxopentanoate (non-preferred name)
butyl 2-[2-[2-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoylamino]-5-amino-5-oxopentanoate

Research Excerpts

Overview

Murabutide (MB) is a synthetic immunomodulator recognized by the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor on mammalian cells. It is in clinical stage of development.

ExcerptReferenceRelevance
"Murabutide is a safe derivative of MDP, which interacts with cells of the immune system, both innate and adaptive, and exerts its effect through activation of Nod2."( Murabutide revisited: a review of its pleiotropic biological effects.
Jakopin, Ž, 2013
)
2.55
"Murabutide (MB) is a synthetic immunomodulator recognized by the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor on mammalian cells. "( Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine.
Herbst-Kralovetz, MM; Jackson, EM, 2012
)
2.12
"Murabutide is a synthetic muramyl peptide which is in clinical stage of development. "( Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue.
Bahr, GM; Darcissac, EC; Parant, MA; Pouillart, PR; Riveau, GJ, 1996
)
1.97
"Murabutide is a safe synthetic immunomodulator presenting a capacity to enhance nonspecific resistance against viral infections and to target cells of the reticuloendothelial system."( The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.
Bahr, GM; Capron, A; Darcissac, EC; Dewulf, J; Mouton, Y; Truong, MJ, 2000
)
1.32
"Murabutide is a safe synthetic immunomodulator derived from muramyl dipeptide, the smallest bioactive unit of bacterial peptidoglycan. "( Enhanced maturation and functional capacity of monocyte-derived immature dendritic cells by the synthetic immunomodulator Murabutide.
Bahr, GM; Dewulf, J; Vidal, V, 2001
)
1.96

Compound-Compound Interactions

ExcerptReferenceRelevance
" leprae antigen(s), in combination with immunomodulators murabutide (MB) and a Trat peptide in particulate form (liposome)."( Inhibition of apoptosis, activation of NKT cell and upregulation of CD40 and CD40L mediated by M. leprae antigen(s) combined with Murabutide and Trat peptide in leprosy patients.
Bisht, V; Chattree, V; Khanna, N; Rao, DN, 2008
)
0.8

Dosage Studied

ExcerptRelevanceReference
" Murabutide did not stimulate human or rabbit cells to release endogenous pyrogen (EP), but murametide induced EP production at the same dosage levels as MDP."( Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative.
Chedid, L; Parant, F; Parant, M; Riveau, G, 1984
)
1.18
" The butyl ester of MDP, which induces no detectable pyrogenicity but retains adjuvanticity, required a 100-fold greater dosage than MDP(L-D) in stimulating SAA synthesis."( Amyloidosis and the serum amyloid A protein response to muramyl dipeptide analogs and different mycobacterial species.
Chedid, L; DeLellis, R; Foss, NT; Garcia, C; McAdam, KP; Rees, RJ; Wolff, SM, 1983
)
0.27
" A dose escalation study identified 100 µg as the optimal MB dosage in mice, based on the magnitude of VLP-specific IgG, IgG1, IgG2a and IgA production in serum and VLP-specific IgA production at distal mucosal sites."( Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine.
Herbst-Kralovetz, MM; Jackson, EM, 2012
)
0.67
" Many of these have confirmed its potential to synergize with cytokines of therapeutic interest in potentiating the tumoricidal activity of macrophages or targeting chronic viral diseases, as well as reducing the cytokine dosage needed to achieve a therapeutic effect."( Murabutide revisited: a review of its pleiotropic biological effects.
Jakopin, Ž, 2013
)
1.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (37.50)18.7374
1990's16 (22.22)18.2507
2000's18 (25.00)29.6817
2010's11 (15.28)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.17 (24.57)
Research Supply Index4.47 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (10.26%)5.53%
Reviews3 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (85.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]